Jemperli finds possible niche in mismatch repair-deficient rectal cancer

GSK may be on its way to carving out a new indication for Jemperli in the crowded PD-1 market, with early data from a Phase II study at ASCO showing a 100% clinical complete response rate in 12 mismatch repair-deficient rectal cancer patients.

In a late-breaking abstract presented during the American Society of Clinical Oncology conference, and in a parallel New England Journal of Medicine paper, Memorial Sloan Kettering researchers showed neoadjuvant therapy with the GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) antibody led to complete responses in all patients followed for at least six months, with no evidence of tumor on MRI, FDG-PET, endoscopic visualization, digital rectal exam or biopsy...